Research co-authored by RTI Health Solutions researchers will be presented at the 2021 Virtual American Diabetes Association 81st Scientific Session.
Risk of acute kidney injury in real-world use of dapagliflozin. Johannes C, Layton JB, Beachier D, Ziemiecki R, Li L, Danysh H, Dinh J, Hunt P, Karlsson C, Chen H, Gilsenan A. Presentation
Risk of acute liver injury in real-world use of dapagliflozin. Johannes C, Layton JB, Beachler D, Ziemiecki R, Li L, Danysh H, Dinh J, Hunt P, Karlsson C, Chen H, Gilsenan A. Poster
Risk of severe complications of urinary tract infection in real-world use of dapagliflozin. Johannes C, Layton JB, Beachler D, Ziemiecki R, Li L, Danysh H, Dinh J, Hunt P, Karlsson C, Chen H, Gilsenan A. Poster
Are we there yet? Increasing use of cardioprotective antihyperglycemic agents in patients with T2D and CVD or CV risk in the US. Mody R, Meyers J, Yu M, Levine J, Davis KL. Poster